Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer

Kerr, M.; McBride, David A.; Chumber, Arun K.; Shah, Naseem

doi:10.1080/17460441.2020.1811673

Cited by 16 publications

(12 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer cells can establish an immunosuppressive microenvironment by inhibiting immune recognition, inducing immune cell apoptosis, and reducing the infiltration of antitumor immune cells (4). It can be speculated that targeted therapy induces antigens release through killing of tumor cells, which in turn initiates and enhances anti-tumor immune responses (67)(68)(69). A number of preclinical studies has suggested the potential of EGFR-TKI in combination with immunotherapy as a treatment for NSCLC.…”

Section: Egfr-tki Combined Immunotherapymentioning

confidence: 99%

“…To prolong the response duration of EGFR mutant NSCLC and delay the onset of drug resistance, clinical trials combining EGFR-TKIs and immunotherapy were conducted. As part of the CHECKMATE 012 study, 21 patients with EGFR mutationpositive NSCLC (20 patients who received erlotinib pretreatment and 1 patient who did not receive EGFR-TKI treatment) were evaluated for safety and efficacy (68). 3 mg/kg nivolumab and 150 mg erlotinib were given every 2 weeks until disease progression or unacceptable toxicity.…”

Section: Egfr-tki Combined Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Peng

Yao²,

Pan³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) represented by gefitinib and erlotinib are widely used in treating non-small cell lung cancer (NSCLC). However, acquired resistance to EGFR-TKI treatment remains a clinical challenge. In recent years, emerging research investigated in EGFR-TKI-based combination therapy regimens, and remarkable achievements have been reported. This article focuses on EGFR-TKI-based regimens, reviews the standard and novel application of EGFR targets, and summarizes the mechanisms of EGFR-TKI combinations including chemotherapy, anti-vascular endothelial growth factor monoclonal antibodies, and immunotherapy in the treatment of NSCLC. Additionally, we summarize clinical trials of EGFR-TKI-based combination therapy expanding indications to EGFR mutation-negative lung malignancies. Moreover, novel strategies are under research to explore new drugs with good biocompatibility. Nanoparticles encapsulating non-coding RNA and chemotherapy of new dosage forms drawn great attention and showed promising prospects in effective delivery and stable release. Overall, as the development of resistance to EGFR-TKIs treatment is inevitable in most of the cases, further research is needed to clarify the underlying mechanism of the resistance, and to evaluate and establish EGFR-TKI combination therapies to diversify the treatment landscape for NSCLC.

show abstract

Section: Egfr-tki Combined Immunotherapymentioning

confidence: 99%

Section: Egfr-tki Combined Immunotherapymentioning

confidence: 99%

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Peng

Yao²,

Pan³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…HAC2‐based cancer neoantigen vaccines would likely require optimization with multiple TLR agonists and multiple antigen targets to improve vaccine efficacy and breadth of the adaptive immune response. Further, efficacy of HAC2‐based neoantigen vaccines could be assessed in combination with checkpoint inhibitor or chemotherapy 52,60,61 . Taken together, our results demonstrate the development of a biodegradable, vaccine which may be leveraged to provide greater protection against infections or cancers, including in settings of immunodeficiency.…”

Section: Discussionmentioning

confidence: 74%

“…7,[48][49][50] To potentially improve cancer vaccine efficacy, particularly in established tumors, combining standard-of-care therapy, for example, chemotherapy or checkpoint inhibitors, with cancer vaccines has proven to be an effective strategy to prolong survival compared with either therapy alone. 2,51,52 The distinct mechanisms by which these agents operate might leverage both pre-existing tumor-specific immune cells and generate new anti-tumor immunity for a potentially stronger and more durable response.…”

Section: Discussionmentioning

confidence: 99%

Biodegradable scaffolds for enhancing vaccine delivery

Kerr,

Johnson,

McBride

et al. 2023

Bioengineering & Transla Med

Self Cite

View full text Add to dashboard Cite

Sustained release of vaccine components is a potential method to boost efficacy compared with traditional bolus injection. Here, we show that a biodegradable hyaluronic acid (HA)‐scaffold, termed HA cryogel, mediates sustained antigen and adjuvant release in vivo leading to a durable immune response. Delivery from subcutaneously injected HA cryogels was assessed and a formulation which enhanced the immune response while minimizing the inflammation associated with the foreign body response was identified, termed CpG‐OVA‐HAC2. Dose escalation studies with CpG‐OVA‐HAC2 demonstrated that both the antibody and T cell responses were dose‐dependent and influenced by the competency of neutrophils to perform oxidative burst. In immunodeficient post‐hematopoietic stem cell transplanted mice, immunization with CpG‐OVA‐HAC2 elicited a strong antibody response, three orders of magnitude higher than dose‐matched bolus injection. In a melanoma model, CpG‐OVA‐HAC2 induced dose‐responsive prophylactic protection, slowing the tumor growth rate and enhancing overall survival. Upon rechallenge, none of the mice developed new tumors suggesting the development of robust immunological memory and long‐lasting protection against repeat infections. CpG‐OVA‐HAC2 also enhanced survival in mice with established tumors. The results from this work support the potential for CpG‐OVA‐HAC2 to enhance vaccine delivery.

show abstract

“…In recent years, researchers have used the relationship between exosomes and the immune system to combine traditional chemotherapy with immunotherapy to develop immunotherapy for tumor treatment ( 285 , 286 ). This immunotherapy targets tumor-derived exosomes as potential antigens and uses TLR3 agonists to generate long-lasting T-cell immune effect and destroy the immune tolerance of the tumor ( 15 , 287 ).…”

Section: Exosomes As Immunotherapy For Ovarian Cancermentioning

confidence: 99%

Exosomes: A potential tool for immunotherapy of ovarian cancer

et al. 2023

View full text Add to dashboard Cite

Ovarian cancer is a malignant tumor of the female reproductive system, with a very poor prognosis and high mortality rates. Chemotherapy and radiotherapy are the most common treatments for ovarian cancer, with unsatisfactory results. Exosomes are a subpopulation of extracellular vesicles, which have a diameter of approximately 30–100 nm and are secreted by many different types of cells in various body fluids. Exosomes are highly stable and are effective carriers of immunotherapeutic drugs. Recent studies have shown that exosomes are involved in various cellular responses in the tumor microenvironment, influencing the development and therapeutic efficacy of ovarian cancer, and exhibiting dual roles in inhibiting and promoting tumor development. Exosomes also contain a variety of genes related to ovarian cancer immunotherapy that could be potential biomarkers for ovarian cancer diagnosis and prognosis. Undoubtedly, exosomes have great therapeutic potential in the field of ovarian cancer immunotherapy. However, translation of this idea to the clinic has not occurred. Therefore, it is important to understand how exosomes could be used in ovarian cancer immunotherapy to regulate tumor progression. In this review, we summarize the biomarkers of exosomes in different body fluids related to immunotherapy in ovarian cancer and the potential mechanisms by which exosomes influence immunotherapeutic response. We also discuss the prospects for clinical application of exosome-based immunotherapy in ovarian cancer.

show abstract

Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer

Cited by 16 publications

References 99 publications

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Biodegradable scaffolds for enhancing vaccine delivery

Exosomes: A potential tool for immunotherapy of ovarian cancer

Contact Info

Product

Resources

About